Table 2

Unadjusted and adjusted HRs for secondary outcomes with adjusted HRs for incidence of cancer stratified by maximum prescribed dose and duration of follow-up with comparators as the reference category

n (%)UnadjustedAdjusted*
Incidence of bowel cancer
    Comparators76 (1.9)1.001.00
    Users40 (1.0)0.41 (0.28–0.61)0.60 (0.38–0.94)
Incidence of lung cancer
    Comparators58 (1.4)1.001.00
    Users35 (0.9)0.49 (0.32–0.74)0.70 (0.43–1.15)
Incidence of breast cancer in women
    Comparators41 (2.2)1.001.00
    Users24 (1.3)0.44 (0.26–0.73)0.60 (0.32–1.10)
Overall mortality
    Comparators1,422 (34.8)1.001.00
    Users609 (14.9)0.32 (0.29–0.35)0.42 (0.38–0.47)
Mortality from cancer
    Comparators248 (6.1)1.001.00
    Users123 (3.0)0.48 (0.39–0.60)0.63 (0.49–0.81)
Incidence of cancer<2 years follow-up*2–4 years follow-up*>4 years follow-up*
    Maximum prescribed dose during follow-up (n)
Low (1,017)3.15 (1.92–5.18)0.99 (0.44–2.25)0.16 (0.06–0.44)
Medium (2,090)1.94 (1.20–3.13)0.51 (0.31–0.82)0.40 (0.27–0.60)
High (978)2.76 (0.56–13.45)0.28 (0.12–0.70)0.15 (0.09–0.25)
  • Data are HR (95% CI) unless otherwise indicated.

  • *Adjusted for age, sex, smoking, deprivation, BMI, A1C, insulin use, and sulphonylurea use.